GlassScriptPhysician profile
Angeli Chopra
NPI 1992105043
$7,778.93
in general payments reported to CMS, 2019-2025
36 companies · $2,192 in 2025
The $2,192 reported for 2025 was more than what 81% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $805 · 2020: $738 · 2021: $775 · 2022: $1,255 · 2023: $737 · 2024: $1,277 · 2025: $2,192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,146 · Education: $60.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,145.65 |
| Education | $60.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,842.08 | 2019-2025 | Rinvoq, Viberzi, Linzess |
| Janssen Biotech, INC. | $587.46 | 2019-2025 | Stelara, Tremfya, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $546.45 | 2019-2024 | Entyvio, Gattex, Eohilia |
| Regeneron Healthcare Solutions, INC. | $473.30 | 2022-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $434.68 | 2019-2025 | Xifaxan |
| Madrigal Pharmaceuticals | $393.02 | 2024-2025 | Rezdiffra, Resmetirom |
| Ironwood Pharmaceuticals, INC | $308.18 | 2019-2024 | Linzess |
| Lilly USA, LLC | $268.27 | 2025 | Omvoh |
| Qol Medical, LLC | $209.24 | 2021-2025 | Sucraid, Sucraid |
| Gilead Sciences, INC. | $202.58 | 2020-2025 | |
| Ipsen Biopharmaceuticals, INC | $189.40 | 2025 | Iqirvo |
| Redhill Biopharma INC. | $185.57 | 2020-2021 | |
| Nestle Healthcare Nutrition INC. | $151.11 | 2021-2023 | |
| Allergan, INC. | $108.32 | 2019 | |
| Janssen Scientific Affairs, LLC | $79.02 | 2025 | Tremfya |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $70.63 | 2021-2023 | Zeposia |
| Ferring Pharmaceuticals INC. | $70.28 | 2019-2023 | Rebyota |
| Phathom Pharmaceuticals, INC. | $68.57 | 2024-2025 | Voquezna |
| Daiichi Sankyo INC. | $61.42 | 2019-2021 | |
| Medtronic, INC. | $61.28 | 2023-2025 | Interstim, Bravo |
| Shionogi INC | $54.41 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $52.99 | 2024-2025 | Zenpep |
| Pfizer INC. | $48.41 | 2022-2023 | |
| Intercept Pharmaceuticals, INC. | $43.88 | 2020-2025 | Ocaliva |
| Dova Pharmaceuticals | $39.67 | 2019 | |
| Ardelyx, INC. | $35.53 | 2025 | Ibsrela |
| Evoke Pharma, INC. | $33.28 | 2024-2025 | |
| Genzyme Corporation | $28.27 | 2023-2024 | |
| Boston Scientific Corporation | $24.38 | 2019 | |
| Axonics, INC. | $21.22 | 2023 | Axonics |
| Sandoz INC. | $16.73 | 2024 | Hyrimoz |
| Celltrion USA INC. | $16.46 | 2025 | Vegzelma |
| Fresenius Kabi USA, LLC | $14.85 | 2023 | Idacio |
| Alfasigma USA, INC. | $14.13 | 2020 | |
| Organon LLC | $12.86 | 2025 | Hadlima, Renflexis |
| Olympus America INC. | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angeli Chopra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.